Abstracts tagged "gout"

Abstract Number: 0240 • ACR Convergence 2023
Gout: A Gateway to Chronic Opioid Use?
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Tuhina Neogi², James O'Dell¹ and Ted R Mikuls³, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Painful gout flares often lead to healthcare visits which, based on prior reports, results in the use of opioid therapy for flare management, despite…
Abstract Number: 0813 • ACR Convergence 2023
Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants
Mariano Andrés¹, Nalia Domínguez-Lirón², Enrique Calvo-Aranda³, Esther Vicente Rabaneda⁴, Agustín Martínez-Sanchís¹, Francisca Sivera⁵, Diana Peiteado⁶, Alejandro Prada⁷, Blanca Garcia⁸, Basilio Rodríguez⁹, BORIS ANTHONY BLANCO CACERES¹⁰, José Antonio Bernal¹¹, Santos Castañeda¹², Laura Barrio⁷, Sonia Minguez⁹, Mónica Vázquez Díaz¹³, José Miguel Senabre¹¹, Cristina Bohorquez¹⁴, Silvia Gómez-Sabater¹⁵, Rocío Caño-Alameda¹⁵ and Eugenio De Miguel¹⁶, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Miguel Hernández University, Alicante, Spain, ³Hospital Universitario Infanta Leonor, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Elda General University Hospital, Elda, Spain, ⁶Hospital La Paz, Madrid, Spain, ⁷Hospital Universitario de Torrejón, Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Fundació Althaia, Manresa, Spain, ¹⁰Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹¹Hospital Marina Baixa, Villajoyosa, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Spain, ¹³Hospital Ramon y Cajal, Madrid, Spain, ¹⁴Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ¹⁵Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The prevalence of sonographic monosodium urate (MSU) crystal deposition and inflammation in patients with gout in remission is unknown. In 2022, we reported a…
Abstract Number: 1114 • ACR Convergence 2023
Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout
Muhammad Danish Sarfraz, Lee Treanor, Savvas Nicolaou and Adnan Sheikh, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: To find out if a Dual energy CT can detect monosodium urate deposition in carotid arteries and whether the presence of monosodium urate crystals…
Abstract Number: 2563 • ACR Convergence 2023
Causal Associations Between Gut Microbiota and Rheumatic Diseases: A Mendelian Randomization Study
Ying Hu¹, Hongyi He², Yuqing Zhang³, Houchen Lyu⁴, Chao Zeng², Jie Wei⁵ and Guanghua Lei², ¹Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China, ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Chinese PLA General Hospital, Department of Orthopedics, Beijing, China, ⁵Health Management Center, Xiangya Hospital Central South University, Changsha, China
Background/Purpose: Gut microbiota has been increasingly recognized as important and novel targets for rheumatic diseases. However, previous studies mostly examined the associations, leaving causality largely…
Abstract Number: 0241 • ACR Convergence 2023
Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial
Austin Barry¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Bridget Kramer¹, Jeff Newcomb⁴, Mary Brophy³, Anne Davis-Karim⁵, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, James O'Dell¹ and Ted R Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Boston VA, Boston, MA, ⁴Omaha VA, Omaha, NE, ⁵Albuquerque VA, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Initiating urate-lowering therapy (ULT) in gout is known to precipitate flares, which can lead to decreased adherence and suboptimal outcomes. Until recently, there has…
Abstract Number: 0814 • ACR Convergence 2023
Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority Trial
Joshua Qu¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Bridget Kramer¹, Jefferey Newcomb⁴, Mary Brophy³, Anne Davis-Karim⁵, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, James O'Dell¹ and Ted R Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Boston VA, Boston, MA, ⁴University of Nebraska, Omaha, NE, ⁵Albuquerque VA, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To optimally manage gout, the ACR recommends a treat-to-target (T2T) strategy, which entailsthe titration of urate-lowering therapy (ULT) to achieve and maintain a serum…
Abstract Number: 1115 • ACR Convergence 2023
EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice
Peter Mandl¹, Maria-Antonietta D'Agostino², Victoria Navarro-Compán³, Irina Gessl¹, Garifallia Sakellariou⁴, Abhishek Abhishek⁵, Fabio Becce⁶, Nicola Dalbeth⁷, Hang-Korng Ea⁸, Emilio Filippucci⁹, Hilde Berner Hammer¹⁰, Annamaria Iagnocco¹¹, Annette De Thurah¹², Esperanza Naredo¹³, Sebastien Ottaviani¹⁴, Tristan Pascart¹⁵, Fernando Perez-Ruiz¹⁶, Irene Pitsillidou¹⁷, Fabian Proft¹⁸, Juergen Rech¹⁹, Wolfgang Schmidt²⁰, Luca Sconfienza²¹, Lene Terslev²², Brigitte Wildner²³, Pascal Zufferey²⁴ and Georgios Filippou²⁵, ¹Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Universita Cattolica del Sacro Cuore Rome, Courbevoie, France, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Department of Internal Medicine and Therapeutics, Università di Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, ⁵University of Nottingham, Nottingham, United Kingdom, ⁶Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁷University of Auckland, Auckland, New Zealand, ⁸Hôpital Lariboisière, APHP-Nord, Service de Rhumatologie, Université de Paris Cité, Paris, France, ⁹Polytechnic University of Marche, Jesi, Italy, ¹⁰Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway AND University of Oslo, Faculty of Medicine, Oslo, Norway, ¹¹University of Turin, Roma, Italy, ¹²Aarhus University Hospital, Aarhus, Denmark, ¹³Hospital Fundación, Madrid, Spain, ¹⁴Assistance Publique Hopitaux de Paris, Paris, France, ¹⁵Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France, ¹⁶Rheumatology Division, Osakidetza, OSI-EE Cruces, Cruces University Hospital, Barakaldo, Spain, ¹⁷EULAR Patient Research Partner, Executive Secretary of Cyprus League Against Rheumatism, Nicosia, Cyprus, ¹⁸Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ¹⁹University Clinic Erlangen, Erlangen, Germany, ²⁰Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ²¹Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano AND IRCCS Istituto Ortopedico Galeazzi, 20161, Milan, Italy, ²²Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ²³University Library, Medical University of Vienna, Vienna, Austria, ²⁴Rheumatology Department, University of Lausanne, CHUV, Lausenne, Switzerland, ²⁵IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy
Background/Purpose: The multifaceted clinical presentation in crystal-induced arthropathies (CiA) poses challenges to imaging. Our goal was to formulate evidence-based recommendations on the use of imaging…
Abstract Number: 0242 • ACR Convergence 2023
Venous Thromboembolism in Patients with Gout in the US
Alka Mithal¹, Maanek Sehgal¹, Brian LaMoreaux² and Gurkirpal Singh¹, ¹ICORE, Woodside, CA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Venous thromboembolism (VTE), manifested by deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common medical problem with an estimated incidence of 1–2…
Abstract Number: 0816 • ACR Convergence 2023
Additive Association of ABCG2 rs4148155 and SLC22A12 rs75786299 Polymorphisms with Hyperuricemia, Gout and Nephrolithiasis, a Hospital-Based, Case-Control Study
Ching-Tsai Lin¹, I-Chieh Chen², Wen-Nan Huang¹, Yi-Hsing Chen¹, Ching-Heng Lin² and Yi-Ming Chen¹, ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: This study aimed to investigate the interaction between the ABCG2 rs4148155 and SLC22A12 rs75786299 variants and their association with incident gout and nephrolithiasis in…
Abstract Number: 1116 • ACR Convergence 2023
The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System
Chio Yokose¹, Baijun Zhou¹, Natalie McCormick¹, Sruthi Tanikella¹, Minna Kohler², Janeth Yinh¹, Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A substantial proportion of gout patients have type 2 diabetes (T2DM), heart failure (HF), and chronic kidney disease (CKD), for which SGLT2i treatment is…
Abstract Number: 0243 • ACR Convergence 2023
Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center
Nishah Panchani¹, Angelo Gaffo² and Vineeta Kumar³, ¹Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham, Arlington, TX, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL, ³Division of Nephrology/Transplant, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout has been associated with high rates of morbidity and mortality in kidney transplant (KT) patients with increased bone destruction and associated cardiovascular and…
Abstract Number: 1008 • ACR Convergence 2023
Identifying Inflammatory Arthritis Ambulatory Care Service Model Enhancements Needed to Reduce Avoidable Emergency Department Use
Emilie Pianarosa¹, Pamela Roach¹, Patrick McLane², Meghan Elliott¹, Brian Holroyd³, Shanon McQuitty⁴, Steven Katz³, Nazret Russon², Katie Lin¹, Claire Barber¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²Alberta Health Services, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Emergency departments (ED) become a location for non-urgent care when ambulatory care systems are not sufficient. We aim to describe contributing factors to the…
Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Chio Yokose¹, Gregory Challener², Baijun Zhou², Natalie McCormick², Sruthi Tanikella², Kila Panchot², Minna Kohler³, Janeth Yinh², Yuqing Zhang⁴, David Bates⁵, James Januzzi², Meghan Sise², Deborah Wexler² and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
Abstract Number: 0244 • ACR Convergence 2023
Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
James Cheng-Chung Wei¹, Roy Fleischmann², sarah Morris³, Vijay Hingorani⁴, Elizabeth Polvent⁵, Zancong Shen⁶, Shunqi Yan⁷, Li-Tain Yeh⁸ and Robert Keenan⁹, ¹Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ²Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Arthrosi Therapeutics, San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁸Arthrosi Therapeutics, Inc., Irvine, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC
Background/Purpose: AR882 is a novel, potent, and selective URAT1inhibitor in development for the treatment of gout and tophaceous gout. AR882-202 was a global, multi-center, randomized,…
Abstract Number: 1012 • ACR Convergence 2023
Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial
Candace Feldman¹, Katherine Crum², Kaitlin Hanken³, Constance Fontanet⁴, Ellen Sears², Theresa Oduol², Seanna Vine², Juliana Mastrorilli², Gauri Bhatkhande², Julie Lauffenburger², Rebecca Oran⁵, Ted Robertson⁶, Wendy Wood⁷ and Niteesh Choudhry³, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Center for Healthcare Delivery Sciences and Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Darmouth Geisel School of Medicine, Hanover, NH, ⁵BCBS, Boston, MA, ⁶Ideas42, San Francisco, CA, ⁷USC, Los Angelos, CA
Background/Purpose: Adherence to urate-lowering therapy (ULT) reduces the incidence of debilitating gout flares. Providing a cue for a behavior, reinforcing the behavior with a reward,…

« Previous Page
1
…
6
7
8
9
10
…
45
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].